Business
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Registrational Trialin Previously Treated Advanced NSCLC in 2H25 SAN CARLOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on in
About this update from Iovance Biotherapeutics, Inc.
[{"type":"image","alt":"Iovance Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Iovance Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.v3WcxvLExw0gdNQeyFn2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520","width":300,"height":98}},"lazy":false},{"type":"text","content":"1Q25 Total Product Revenue of $49.3M","length":36,"tagName":"p"},{"type":"text","content":"FY25 Total Product Revenue Guidance Revised to $250M-$300M ","length":58,"tagName":"p"},{"type":"text","content":"FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained","length":72,"tagName":"p"},{"type":"text","content":"2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada ","length":73,"tagName":"p"},{"type":"text","content":"On Track to Report Updated Clinical Data for Registrational Trialin Previously Treated Advanced NSCLC in 2H25","length":110,"tagName":"p"},{"type":"text","content":"SAN CARLOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2025 financial results and corporate updates.","length":347,"tagName":"p"},{"type":"text","content":"Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “During the start of the new year, our first quarter revenue was impacted by a significant reduction in capacity during the annual scheduled maintenance at the Iovance Cell Therapy Center (iCTC). Since full production has now resumed at the iCTC, we now expect infusions to grow in the second quarter as compared to the first quarter. Additionally, based on our experience to date, we are revising full-year 2025 revenue guidance to reflect recent launch dynamics. In the first 12 months of our U.S. launch, we have executed toward our long-term adoption goals by treating more than 275 Amtagvi patients and generating more than $210 million in revenue. Beyond the U.S. launch, we are on track this...